Cardiovascular outcome trials (CVOTs) have shown that SGLT2s reduce hospitalisations for heart failure and chronic kidney disease (CKD), while GLP-1 RAs reduce stroke and major adverse cardiovascular events (MACE)
If you have not started to lose weight by the time you reach this dose, or have lost less than 5% of your starting weight, speak to your doctor or pharmacist
Olmestig J, Marlet IR, Vilsboll T et al (2022) A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: randomized, placebo-controlled, double-blind clinical trial
doi: 10.3389/fendo.2023.1139444 100 SuzukiCTanidaIOliva TrejoJAKakutaSUchiyamaY
Some are research-grade peptides used in clinical settings, while others are low-dose, supplement-style capsules with little proven efficacy
PMID: 38156967